Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.04 USD
-0.03 (-1.44%)
Updated Jul 24, 2024 03:56 PM ET
After-Market: $2.04 0.00 (0.00%) 6:40 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLLS 2.04 -0.03(-1.44%)
Will CLLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLLS
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cellectis (CLLS) Upgraded to Buy: Here's Why
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Other News for CLLS
Cellectis treatment of acute lymphoblastic leukemia granted orphan designation
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Cellectis Shareholders Approve Key Resolutions
Cellectis Shareholders Support Management’s Vision
Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits